TY - JOUR
T1 - Clinical use of biologics for asthma treatment by allergy specialists
T2 - A questionnaire survey
AU - Kuruvilla, Merin
AU - Ariue, Barbara
AU - Oppenheimer, John J.
AU - Singh, Umesh
AU - Bernstein, Jonathan A.
N1 - Publisher Copyright:
© 2020 American College of Allergy, Asthma & Immunology
PY - 2020/10
Y1 - 2020/10
N2 - Background: Asthma is a heterogeneous disease with emerging phenotypes and endotypes. At present, 5 distinct biologics are Food and Drug Administration–approved as an add-on therapy for difficult-to-control type 2–high asthma. Because allergy specialists manage a spectrum of diseases for which biologics may be appropriate, it is important to understand their prescribing patterns. Objective: To elucidate the allergist's use of biologics in the treatment of asthma, including barriers, preferences, indications for prescribing, measures to determine effectiveness, and cost-effectiveness. Methods: A survey was performed among allergists using a semistructured 10-item self-administered web-based questionnaire and the responses were analyzed using one-way frequencies and multiple logistic regression. Results: The response rate was approximately 9%. Omalizumab was the most prescribed biologic for asthma (98%), and “uncontrolled asthma despite adherence to controller medication” was the most common reason. The common selection criteria among the biologics included elevated peripheral eosinophil count, asthma with nasal polyps, and asthma type (type 1; type 2; nonallergic). A decreased exacerbation frequency was the best standard to determine the efficacy among biologics. Benralizumab was considered the most cost-effective. Conclusion: This study represents one of the largest surveys among allergy specialists regarding the real-world use of asthma biologics. It seems that there has been reasonably good dissemination and application of current guidelines among allergists based on prescribing patterns. However, their responses reflect the need for the continued modification of asthma guidelines that incorporate novel biologics and other pathway-specific agents into step therapy. As clinical phenotypes and predictive biomarkers develop, allergy specialists will be better prepared to practice precision medicine that optimizes the use of asthma biologics.
AB - Background: Asthma is a heterogeneous disease with emerging phenotypes and endotypes. At present, 5 distinct biologics are Food and Drug Administration–approved as an add-on therapy for difficult-to-control type 2–high asthma. Because allergy specialists manage a spectrum of diseases for which biologics may be appropriate, it is important to understand their prescribing patterns. Objective: To elucidate the allergist's use of biologics in the treatment of asthma, including barriers, preferences, indications for prescribing, measures to determine effectiveness, and cost-effectiveness. Methods: A survey was performed among allergists using a semistructured 10-item self-administered web-based questionnaire and the responses were analyzed using one-way frequencies and multiple logistic regression. Results: The response rate was approximately 9%. Omalizumab was the most prescribed biologic for asthma (98%), and “uncontrolled asthma despite adherence to controller medication” was the most common reason. The common selection criteria among the biologics included elevated peripheral eosinophil count, asthma with nasal polyps, and asthma type (type 1; type 2; nonallergic). A decreased exacerbation frequency was the best standard to determine the efficacy among biologics. Benralizumab was considered the most cost-effective. Conclusion: This study represents one of the largest surveys among allergy specialists regarding the real-world use of asthma biologics. It seems that there has been reasonably good dissemination and application of current guidelines among allergists based on prescribing patterns. However, their responses reflect the need for the continued modification of asthma guidelines that incorporate novel biologics and other pathway-specific agents into step therapy. As clinical phenotypes and predictive biomarkers develop, allergy specialists will be better prepared to practice precision medicine that optimizes the use of asthma biologics.
UR - http://www.scopus.com/inward/record.url?scp=85088388904&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85088388904&partnerID=8YFLogxK
U2 - 10.1016/j.anai.2020.06.041
DO - 10.1016/j.anai.2020.06.041
M3 - Article
C2 - 32629016
SN - 1081-1206
VL - 125
SP - 433
EP - 439
JO - Annals of Allergy, Asthma and Immunology
JF - Annals of Allergy, Asthma and Immunology
IS - 4
ER -